Pilot study using a humanized CC49 monoclonal antibody (HuCC49ΔC H2) to localize recurrent colorectal carcinoma

Doreen M. Agnese, Shahab F. Abdessalam, William E. Burak, Mark W. Arnold, Denise Soble, George H. Hinkle, Donn Young, M. B. Khazaeli, Edward W. Martin

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: CC49 is a monoclonal antibody directed against a pancarcinoma antigen (TAG-72) expressed by colorectal cancers. The use of murine CC49 in radioimmunoguided surgery (RIGS) was problematic because of the human anti-mouse antibodies (HAMA) generated. This study was designed to assess the clearance, safety, and effectiveness of localization of a complimentarity determining region (CDR)-grafted humanized domain-deleted antitumor CC49 antibody (HuCC49ΔCH2). Methods: After thyroid blockade, 1 mg of HuCC49ΔCH2 radiolabeled with 2 mCi of iodine-125 was administered. All patients subsequently underwent traditional exploration followed by a survey with the gamma-detecting probe. In five patients, exploration was performed 10 to 24 days after injection, when precordial counts were sufficiently low (<30 counts per 2 seconds [cp2s]). Traditionally suggestive and probe-positive tissue was biopsied or excised and examined for the presence of carcinoma, when considered appropriate by the operating surgeon. Serum was assessed for HAMA. Results: Seventeen sites were identified as suggestive of carcinoma on traditional exploration and 21 by RIGS. Of these, pathologic correlation was obtained in 15. The sensitivity of RIGS was 92%, and the positive predictive value was 100%. None of the patients expressed significant HAMA. Conclusions: This initial study indicates that the HuCC49ΔCH2 monoclonal antibody, when used with RIGS, is safe and sensitive in detecting recurrent intra-abdominal colon cancer.

Original languageEnglish (US)
Pages (from-to)197-202
Number of pages6
JournalAnnals of Surgical Oncology
Volume11
Issue number2
DOIs
StatePublished - Dec 1 2004

Fingerprint

Colorectal Neoplasms
Anti-Idiotypic Antibodies
Monoclonal Antibodies
Carcinoma
Iodine
Colonic Neoplasms
Thyroid Gland
Safety
Antigens
Injections
B72.3 antibody
Serum

Keywords

  • Colorectal carcinoma
  • Monoclonal antibody
  • RIGS
  • Recurrent

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Pilot study using a humanized CC49 monoclonal antibody (HuCC49ΔC H2) to localize recurrent colorectal carcinoma. / Agnese, Doreen M.; Abdessalam, Shahab F.; Burak, William E.; Arnold, Mark W.; Soble, Denise; Hinkle, George H.; Young, Donn; Khazaeli, M. B.; Martin, Edward W.

In: Annals of Surgical Oncology, Vol. 11, No. 2, 01.12.2004, p. 197-202.

Research output: Contribution to journalArticle

Agnese, DM, Abdessalam, SF, Burak, WE, Arnold, MW, Soble, D, Hinkle, GH, Young, D, Khazaeli, MB & Martin, EW 2004, 'Pilot study using a humanized CC49 monoclonal antibody (HuCC49ΔC H2) to localize recurrent colorectal carcinoma', Annals of Surgical Oncology, vol. 11, no. 2, pp. 197-202. https://doi.org/10.1245/ASO.2004.05.010
Agnese, Doreen M. ; Abdessalam, Shahab F. ; Burak, William E. ; Arnold, Mark W. ; Soble, Denise ; Hinkle, George H. ; Young, Donn ; Khazaeli, M. B. ; Martin, Edward W. / Pilot study using a humanized CC49 monoclonal antibody (HuCC49ΔC H2) to localize recurrent colorectal carcinoma. In: Annals of Surgical Oncology. 2004 ; Vol. 11, No. 2. pp. 197-202.
@article{cbfd12e881474ae5a1c300985865a240,
title = "Pilot study using a humanized CC49 monoclonal antibody (HuCC49ΔC H2) to localize recurrent colorectal carcinoma",
abstract = "Background: CC49 is a monoclonal antibody directed against a pancarcinoma antigen (TAG-72) expressed by colorectal cancers. The use of murine CC49 in radioimmunoguided surgery (RIGS) was problematic because of the human anti-mouse antibodies (HAMA) generated. This study was designed to assess the clearance, safety, and effectiveness of localization of a complimentarity determining region (CDR)-grafted humanized domain-deleted antitumor CC49 antibody (HuCC49ΔCH2). Methods: After thyroid blockade, 1 mg of HuCC49ΔCH2 radiolabeled with 2 mCi of iodine-125 was administered. All patients subsequently underwent traditional exploration followed by a survey with the gamma-detecting probe. In five patients, exploration was performed 10 to 24 days after injection, when precordial counts were sufficiently low (<30 counts per 2 seconds [cp2s]). Traditionally suggestive and probe-positive tissue was biopsied or excised and examined for the presence of carcinoma, when considered appropriate by the operating surgeon. Serum was assessed for HAMA. Results: Seventeen sites were identified as suggestive of carcinoma on traditional exploration and 21 by RIGS. Of these, pathologic correlation was obtained in 15. The sensitivity of RIGS was 92{\%}, and the positive predictive value was 100{\%}. None of the patients expressed significant HAMA. Conclusions: This initial study indicates that the HuCC49ΔCH2 monoclonal antibody, when used with RIGS, is safe and sensitive in detecting recurrent intra-abdominal colon cancer.",
keywords = "Colorectal carcinoma, Monoclonal antibody, RIGS, Recurrent",
author = "Agnese, {Doreen M.} and Abdessalam, {Shahab F.} and Burak, {William E.} and Arnold, {Mark W.} and Denise Soble and Hinkle, {George H.} and Donn Young and Khazaeli, {M. B.} and Martin, {Edward W.}",
year = "2004",
month = "12",
day = "1",
doi = "10.1245/ASO.2004.05.010",
language = "English (US)",
volume = "11",
pages = "197--202",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Pilot study using a humanized CC49 monoclonal antibody (HuCC49ΔC H2) to localize recurrent colorectal carcinoma

AU - Agnese, Doreen M.

AU - Abdessalam, Shahab F.

AU - Burak, William E.

AU - Arnold, Mark W.

AU - Soble, Denise

AU - Hinkle, George H.

AU - Young, Donn

AU - Khazaeli, M. B.

AU - Martin, Edward W.

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Background: CC49 is a monoclonal antibody directed against a pancarcinoma antigen (TAG-72) expressed by colorectal cancers. The use of murine CC49 in radioimmunoguided surgery (RIGS) was problematic because of the human anti-mouse antibodies (HAMA) generated. This study was designed to assess the clearance, safety, and effectiveness of localization of a complimentarity determining region (CDR)-grafted humanized domain-deleted antitumor CC49 antibody (HuCC49ΔCH2). Methods: After thyroid blockade, 1 mg of HuCC49ΔCH2 radiolabeled with 2 mCi of iodine-125 was administered. All patients subsequently underwent traditional exploration followed by a survey with the gamma-detecting probe. In five patients, exploration was performed 10 to 24 days after injection, when precordial counts were sufficiently low (<30 counts per 2 seconds [cp2s]). Traditionally suggestive and probe-positive tissue was biopsied or excised and examined for the presence of carcinoma, when considered appropriate by the operating surgeon. Serum was assessed for HAMA. Results: Seventeen sites were identified as suggestive of carcinoma on traditional exploration and 21 by RIGS. Of these, pathologic correlation was obtained in 15. The sensitivity of RIGS was 92%, and the positive predictive value was 100%. None of the patients expressed significant HAMA. Conclusions: This initial study indicates that the HuCC49ΔCH2 monoclonal antibody, when used with RIGS, is safe and sensitive in detecting recurrent intra-abdominal colon cancer.

AB - Background: CC49 is a monoclonal antibody directed against a pancarcinoma antigen (TAG-72) expressed by colorectal cancers. The use of murine CC49 in radioimmunoguided surgery (RIGS) was problematic because of the human anti-mouse antibodies (HAMA) generated. This study was designed to assess the clearance, safety, and effectiveness of localization of a complimentarity determining region (CDR)-grafted humanized domain-deleted antitumor CC49 antibody (HuCC49ΔCH2). Methods: After thyroid blockade, 1 mg of HuCC49ΔCH2 radiolabeled with 2 mCi of iodine-125 was administered. All patients subsequently underwent traditional exploration followed by a survey with the gamma-detecting probe. In five patients, exploration was performed 10 to 24 days after injection, when precordial counts were sufficiently low (<30 counts per 2 seconds [cp2s]). Traditionally suggestive and probe-positive tissue was biopsied or excised and examined for the presence of carcinoma, when considered appropriate by the operating surgeon. Serum was assessed for HAMA. Results: Seventeen sites were identified as suggestive of carcinoma on traditional exploration and 21 by RIGS. Of these, pathologic correlation was obtained in 15. The sensitivity of RIGS was 92%, and the positive predictive value was 100%. None of the patients expressed significant HAMA. Conclusions: This initial study indicates that the HuCC49ΔCH2 monoclonal antibody, when used with RIGS, is safe and sensitive in detecting recurrent intra-abdominal colon cancer.

KW - Colorectal carcinoma

KW - Monoclonal antibody

KW - RIGS

KW - Recurrent

UR - http://www.scopus.com/inward/record.url?scp=2342544825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342544825&partnerID=8YFLogxK

U2 - 10.1245/ASO.2004.05.010

DO - 10.1245/ASO.2004.05.010

M3 - Article

C2 - 14761924

AN - SCOPUS:2342544825

VL - 11

SP - 197

EP - 202

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 2

ER -